Article
Clinical Neurology
Marja Niiranen, Aleksi Kontkanen, Olli Jaaskelainen, Hanna-Mari Tertsunen, Tuomas Selander, Paivi Hartikainen, Nadine Huber, Eino Solje, Annakaisa Haapasalo, Tarja Kokkola, Tarja Lohioja, Sanna-Kaisa Herukka, Sakari Simula, Anne M. Remes
Summary: The study found significantly elevated serum GFAP levels in both BRRMS and ARRMS patients compared to healthy controls, with no significant differences between BRRMS and ARRMS. There were also no significant differences in serum NfL levels among the groups.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Neurosciences
Marie Dreger, Robert Steinbach, Nayana Gaur, Klara Metzner, Beatrice Stubendorff, Otto W. Witte, Julian Grosskreutz
Summary: The study investigated the correlation between CSF NfL levels and disease aggressiveness in ALS using the D50 disease progression model. Significant differences in NfL concentrations were found between different disease aggressiveness subgroups, indicating an increase of NfL levels with more aggressive disease progression. The study suggests that CSF NfL could potentially serve as a biomarker for disease aggressiveness in ALS, but further research is needed to address analytical variations.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Clinical Neurology
Christian Barro, Brian C. Healy, Yanqing Liu, Shrishti Saxena, Anu Paul, Mariann Polgar-Turcsanyi, Charles R. G. Guttmann, Rohit Bakshi, Harald Kropshofer, Howard L. Weiner, Tanuja Chitnis
Summary: Neurodegeneration and astrocytic activation are characteristic pathological features of progressive MS. sNfL and sGFAP can be used as tools to stratify patients based on progression and disease activity status.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2023)
Article
Immunology
Benjamin Vlad, Ina Reichen, Stephan Neidhart, Marc Hilty, Dimitra Lekaditi, Christine Heuer, Amanda Eisele, Mario Ziegler, Markus Reindl, Andreas Lutterotti, Axel Regeniter, Ilijas Jelcic
Summary: Basic CSF parameters vary considerably in different clinical phenotypes of MOGAD. Q(Alb)>10x10(-3) and absence of CSF-restricted OCB are highly useful to differentiate MOGAD from MS.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Clinical Neurology
Anniina Snellman, Juan Lantero-Rodriguez, Andreja Emersic, Agathe Vrillon, Thomas K. Karikari, Nicholas J. Ashton, Milica Gregoric Kramberger, Sasa Cucnik, Claire Paquet, Uros Rot, Henrik Zetterberg, Kaj Blennow
Summary: The study develops new N-terminal-directed CSF total tau assays, which show increased levels ahead of standard t-tau in the Alzheimer's disease continuum, higher levels in patients with CJD or acute neurological diseases, and better potential as Alzheimer's disease blood biomarkers compared to Quanterix total tau.
Article
Biochemistry & Molecular Biology
Tamas Biernacki, Zsofia Kokas, Daniel Sandi, Judit Fuvesi, Zsanett Fricska-Nagy, Peter Farago, Tamas Zsigmond Kincses, Peter Klivenyi, Krisztina Bencsik, Laszlo Vecsei
Summary: MS is a common chronic neurodegenerative disease affecting young people, with significant impact on quality of life. Early recognition and treatment are crucial. Current therapies aim to reduce disease activity, but monitoring measures have limitations. New biomarkers in blood and CSF may improve diagnostic accuracy and personalized treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Nils G. Margraf, Justina Dargvainiene, Emily Theel, Frank Leypoldt, Wolfgang Lieb, Andre Franke, Klaus Berger, Jens Kuhle, Gregor Kuhlenbaeumer
Summary: This study investigates the potential of neurofilament light chain (NfL) in serum and cerebrospinal fluid as a biomarker for neurodestruction in status epilepticus. The results suggest that the concentration of NfL is mainly determined by the duration of status epilepticus, rather than the type of status or treatment refractoriness.
JOURNAL OF NEUROLOGY
(2023)
Article
Medical Laboratory Technology
Olli S. Mattila, Nicholas J. Ashton, Kaj Blennow, Henrik Zetterberg, Heini Harve-Rytsala, Saana Pihlasviita, Juhani Ritvonen, Gerli Sibolt, Tiina Nukarinen, Sami Curtze, Daniel Strbian, Mikko Pystynen, Turgut Tatlisumak, Markku Kuisma, Perttu J. Lindsberg
Summary: This study demonstrates the potential of plasma GFAP and total tau measurements in aiding the differentiation of acute cerebral ischemia and hemorrhagic stroke in the prehospital setting. Monitoring the GFAP release rate can improve early subtype differentiation in stroke patients, particularly in ruling out hemorrhagic stroke.
CLINICAL CHEMISTRY
(2021)
Review
Biochemistry & Molecular Biology
Sarah Holper, Rosie Watson, Nawaf Yassi
Summary: The advances in tau detection have revolutionized the diagnosis of neurodegenerative diseases, offering improved diagnostic accuracy and potential as a predictor of clinical progression and drug therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Stephanie N. Blandford, Neva J. Fudge, Craig S. Moore
Summary: In this study, elevated levels of CXCL10 were detected in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) cases, and these levels were associated with increased T cell numbers but not with peripheral CXCR3 expression. These findings support the importance of CXCL10 in MS and suggest the presence of alternative mechanisms of CXCL10 beyond solely influencing immune cell trafficking.
Article
Medicine, Research & Experimental
Fei Ye, Tianzhu Wang, Xiaoxin Wu, Jie Liang, Jiaoxing Li, Wenli Sheng
Summary: This study identified potential diagnostic biomarkers for progressive multiple sclerosis (PMS) based on m6A regulatory genes in the cerebrospinal fluid. The study revealed that the dynamic modification of m6A RNA methylation is involved in the progression of PMS, and could potentially serve as a novel biomarker for diagnosing MS and differentiating PMS from RRMS.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Clinical Neurology
Nik Krajnc, Patrick Altmann, Katharina Riedl, Christoph Mitsch, Thomas Berger, Fritz Leutmezer, Paulus Rommer, Berthold Pemp, Gabriel Bsteh
Summary: This study investigated the association between cerebrospinal fluid (CSF) parameters at the time of multiple sclerosis (MS) diagnosis and retinal thinning. The results showed an inverse association between CSF white blood cell count and retinal thickness at diagnosis. However, other CSF parameters and neurofilament light chain measurements were not associated with retinal thinning.
FRONTIERS IN NEUROLOGY
(2022)
Review
Neurosciences
Aurelien Lathuiliere, Bradley T. Hyman
Summary: The ability of tau aggregates to recruit and misfold monomeric tau and propagate across brain regions is now recognized as a critical pathological step in Alzheimer's disease and other tauopathies. Recent evidence suggests that the detection of tau seeds in human samples may be relevant and correlate with clinical data, showing the potential for the development of next-generation biomarkers.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Cell Biology
Franz Felix Konen, Philipp Schwenkenbecher, Konstantin Fritz Jendretzky, Stefan Gingele, Kurt-Wolfram Suhs, Hayrettin Tumani, Marie Suesse, Thomas Skripuletz
Summary: Free light chains (FLC), particularly the kappa isoform (KFLC), show high diagnostic sensitivity and specificity in detecting intrathecal inflammation in central nervous system diseases. The measurement of KFLC is fully automated, stable against most influencing factors, and represents a promising diagnostic approach for neuroinflammatory diseases. Further multicenter studies are needed to establish the diagnostic sensitivity and specificity of KFLC, using standardized cut-off values and non-linear formulas.
Article
Clinical Neurology
Eleonora Virgilio, Domizia Vecchio, Ilaria Crespi, Chiara Puricelli, Paolo Barbero, Giulia Galli, Roberto Cantello, Umberto Dianzani, Cristoforo Comi
Summary: Cognitive impairment is a common and disabling symptom in patients with multiple sclerosis. This study found that levels of Tau protein in cerebrospinal fluid may be related to cognitive impairment in the early stages, particularly in patients with slowed information processing speed.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Darin T. Okuda, Orhun Kantarci, Christine Lebrun-Frenay, Maria Pia Sormani, Christina J. Azevedo, Francesca Bovis, Le H. Hua, Lilyana Amezcua, Ellen M. Mowry, Christophe Hotermans, Jason Mendoza, John S. Walsh, Christian von Hehn, Wendy S. Vargas, Stacy Donlon, Robert T. Naismith, Annette Okai, Gabriel Pardo, Pavle Repovic, Olaf Stuve, Aksel Siva, Daniel Pelletier
Summary: This study evaluated the impact of therapeutic intervention in preventing the first symptom manifestation in individuals with radiologically isolated syndrome (RIS), the pre-clinical phase of multiple sclerosis (MS). The results showed that drug treatment significantly reduced the risk of clinical symptoms.
ANNALS OF NEUROLOGY
(2023)
Article
Rheumatology
Merve Ozkilinc Onen, Umut Onat, Serdal Ugurlu, Ahmet C. Timucin, Devrim Oz Arslan, Elif Everest, Huri Ozdogan, Eda Tahir Turanli
Summary: This study identified a rare PSTPIP1 mutation in a family with an FMF and MKD overlapping phenotype but no MEFV and MVK pathogenic variants, suggesting that this variant may cause inflammation response through enhanced PSTPIP1-pyrin interaction and pyrin inflammasome activation.
Article
Clinical Neurology
Bade Gulec, Elif Everest, Ogeday Derin Gorkey, Metehan Koc, Melih Tutuncu, Sabahattin Saip, Aksel Siva, Ugur Uygunoglu
Summary: Patients with multiple sclerosis (MS) who experience rebound activity after discontinuing fingolimod do not show significant changes in long-term outcomes if the rebound activity is well-monitored and treated.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study developed a European consensus on vaccination strategies for people with multiple sclerosis (pwMS) who are candidates for disease-modifying therapies (DMTs). A multidisciplinary working group used formal consensus methodology to formulate recommendations based on the quality of evidence and risk-benefit balance. A total of 53 recommendations were agreed upon, aiming to homogenize immunization practices in pwMS.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Ceren Bibinoglu Amirov, Sema Saltik, Cengiz Yalcinkaya, Melih Tutuncu, Sabahattin Saip, Aksel Siva, Ugur Uygunoglu
Summary: This study describes the use of Ocrelizumab as a disease-modifying drug for pediatric patients with relapsing-remitting multiple sclerosis (P-RRMS). The results show that Ocrelizumab can effectively reduce relapse rate and improve lesion activity, with good safety profile.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
(2023)
Article
Clinical Neurology
Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Mario Alberto Battaglia, Roberto Bergamaschi, Giampaolo Brichetto, S. Destan Bunul, Massimiliano Calabrese, Marco Capobianco, Paola Cavalla, Maria Grazia Celani, Marinella Clerico, Eleonora Cocco, Giancarlo Comi, Paolo Confalonieri, Antonella Conte, Cinzia Cordioli, Giovanna De Luca, Nicola De Rossi, Massimo Filippi, Haluk Gumes, Paolo Immovilli, Matilde Inglese, Rana Karabudak, Doriana Landi, Roberta Lanzillo, Maria Rita L'Episcopo, Lorena Lorefice, Vittorio Mantero, Sabrina Marangoni, Girolama Alessandra Marfia, Camilla Masciulli, Eva Milano, Lucia Moiola, Riccardo Orlandi, Francesco Patti, Paola Perini, Ilaria Pesci, Eugenio Pucci, Marco Puthenparampil, Marta Radaelli, Marco Salvetti, Arianna Sartori, Cinzia Scandellari, Sedat Sen, Aksel Siva, Silvia Strumia, Francesco Teatini, Gioacchino Tedeschi, Maria Trojano, Melih Tutuncu, Giovanna Vaula, Maria Pia Sormani, Maria Pia Amato
Summary: In this multicenter study, researchers evaluated the clinical outcomes of COVID-19 in pregnant patients with multiple sclerosis. The study found no significant increase in severe COVID-19 outcomes in multiple sclerosis patients who contracted the infection during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Review
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study aims to develop an evidence-based vaccination strategy for pwMS who are candidates for disease-modifying therapies. A multidisciplinary working group conducted a systematic literature search and formulated 53 recommendations based on the quality of evidence. The goal of this study is to homogenize immunization practices in pwMS.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Mikael Cohen, Oceane Thomel-Rocchi, Aksel Siva, Darin T. Okuda, Rana Karabudak, Husnu Efendi, Murat Terzi, Clarisse Carra-Dalliere, Francoise Durand-Dubief, Eric Thouvenot, Jonathan Ciron, Helene Zephir, Bertrand Bourre, Olivier Casez, Jerome De Seze, Thibault Moreau, Jean-Philippe Neau, Daniel Pelletier, Orhun Kantarci, Melih Tutuncu, Nathalie Derache, Caroline Bensa, Celine Louapre, Jeanne Benoit, Cassandre Landes-Chateau, Christine Lebrun-Frenay
Summary: A study on individuals with radiologically isolated syndrome (RIS) found that COVID-19 vaccination or infection does not increase the risk of disease activity. Therefore, COVID-19 vaccination can be safely administered and repeated for these individuals.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Multidisciplinary Sciences
Elif Everest, Ugur Uygunoglu, Melih Tutuncu, Alper Bulbul, Umut Inci Onat, Mehmetcan Unal, Timucin Avsar, Sabahattin Saip, Ugur Bilge, Eda Tahir Turanli, Aksel Siva
Summary: This study analyzed a cohort of multiple sclerosis (MS) patients with initial cerebrospinal fluid (CSF) proteomics data to identify disability markers for long-term outcomes. The levels of CSF alpha-2-macroglobulin, apo-A1, and haptoglobin proteins, as well as cerebral lesion load, gait disturbance, and bladder/bowel symptoms, were higher in the unfavorable course group. Conversely, optic nerve involvement and optic neuritis were more frequent in the favorable course group. Therefore, these initial CSF protein levels, along with clinical and radiological parameters, have predictive value for long-term disability in MS cases.
Article
Medicine, Legal
Merve Hazal Ser, Fatma Zehra calikusu, Nursena Erener, Orhan Destanoglu, Ertugrul Kiykim, Aksel Siva
Summary: Auto-brewery syndrome (ABS) is a rare condition where the gut microbiota produces intoxicating amounts of alcohol. It has medicolegal implications in terms of malingering and social problems, and can also result in cognitive and behavioral disturbances. The case presented in this study highlights the neurocognitive consequences of ABS and emphasizes its treatability and relatively benign nature.
JOURNAL OF FORENSIC AND LEGAL MEDICINE
(2023)
Article
Cell Biology
Zehra Degirmenci, Sena Unver, Turker Kilic, Timucin Avsar
Summary: The effect of MEG3 on glioma cells and the potential use of chemotherapeutics in glioma by modulating MEG3 expression were evaluated. Silencing of MEG3 inhibited cell proliferation and migration, while overexpression of MEG3 promoted proliferation in glioma cells. Moreover, MEG3 inhibition improved the chemosensitivity of glioma cells to 5-fluorouracil.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2023)
Review
Clinical Neurology
Merve Aktan Suzgun, Elif Everest, Selin Kucukyurt, Melih Tutuncu, Ugur Uygunoglu, Ahmet Emre Eskazan, Ugur Ture, Herbert Budka, Aydin Sav, Aksel Siva
Summary: Erdheim-Chester disease is a syndrome characterized by histiocytic infiltration of various organs and systems in the body. When the disease only affects the central nervous system (CNS), it is challenging to diagnose due to the absence of systemic symptoms, leading to misdiagnosis and ineffective treatment choices.
Article
Clinical Neurology
Christine Lebrun-Frenay, Aksel Siva, Maria Pia Sormani, Cassandre Landes-Chateau, Lydiane Mondot, Francesca Bovis, Patrick Vermersch, Caroline Papeix, Eric Thouvenot, Pierre Labauge, Francoise Durand-Dubief, Husnu Efendi, Emmanuelle Le Page, Murat Terzi, Nathalie Derache, Bertrand Bourre, Robert Hoepner, Rana Karabudak, Jerome De Seze, Jonathan Ciron, Pierre Clavelou, Sandrine Wiertlewski, Omer Faruk Turan, Nur Yucear, Mikael Cohen, Christina Azevedo, Orhun H. Kantarci, Darin T. Okuda, Daniel Pelletier, TERIS Study Grp
Summary: Radiologically isolated syndrome (RIS) is the earliest detectable preclinical phase of multiple sclerosis (MS) and can be identified through incidental magnetic resonance imaging (MRI) white matter anomalies. This study demonstrates that treatment with teriflunomide can delay the onset of symptoms consistent with MS. The results show that teriflunomide significantly reduces the risk of a first clinical demyelinating event in individuals with RIS.
Article
Clinical Neurology
Sedat Sen, Asli Tuncer, Murat Terzi, Sena Destan Bunul, Pinar Ozen-Acar, Burcu Altunrende, Serkan Ozakbas, Melih Tutuncu, Ugur Uygunoglu, Gulsen Akman-Demir, Rana Karabudak, Husnu Efendi, Aksel Siva
Summary: This study evaluated the prognosis and outcomes of Turkish patients with AQP4-IgG+ NMOSD who received Eculizumab treatment. The findings suggest that Eculizumab is effective and safe for patients with high disease activity, but disease reactivation may occur after discontinuation of the treatment.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Letter
Clinical Neurology
Axel Petzold, Yaou Liu